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Management of intracranial bleeding associated with dabigatran use in a neuroscience hospital
Alejandro Perez, MD; Lynda Thomson, Pharm D; Geno J Merli, MD
Jefferson Vascular Center, Thomas Jefferson University Hospital

ABSTRACT SUMMARY
Background: Dabigatran, an alternative to warfarin for prevention of stroke
with non-valvular atrial fibrillation (AF), offers advantages of a fixed dosage,
minimal laboratory monitoring and limited medication interactions.
Dabigatran requires dosage adjustment in renal dysfunction and is
contraindicated if severe dysfunction. No identified dabigatran reversal agent
exists.
Methods: As part of an ongoing quality initiative, novel anticoagulant
associated adverse events (AE) are monitored at a dedicated neuroscience
hospital.
Results: 5 cases of intracranial bleeding associated with dabigatran occurred
from 12/2011-4/2012. All patients were on anticoagulation for AF, the most
common dose of dabigatran was 150 mg BID. Mean admission values were as
follows: age 83.2 yrs (range 79-90), serum creatinine 1.48 mg/dL (range 0.93.5), creatinine clearance 45.6 mL/min (18-59) and aPTT 49 seconds (range 3260). Strategies for the management of bleeding included withholding
dabigatran, supportive care, administration of blood products and
hemodialysis, when required. Dialysis was initiated on 3 patients. One patient
had 3 dialysis sessions in an effort to normalize coagulation assays and had
transfusions with 10 units of platelets and 4 units of fresh frozen plasma in an
effort to stabilize bleeding. One patient died. Mean time for aPTT to normalize
when abnormal on admission was 30.8 hours (range 21-37).
Conclusions: Appropriate patient selection is required to prevent dabigatran
associated AE, especially in the setting of advanced age and kidney
dysfunction. aPTT values may remain prolonged for extended periods,
despite efforts to normalize. Hospitals need a defined management plan for
major bleeding associated with novel anticoagulants.

BACKGROUND
 Vitamin K antagonists (VKAs), such as
warfarin, have been the mainstay of
therapy for long-term anticoagulation
management of AF for over 60 years.
Unfortunately, VKAs have:
 a slow onset of therapeutic effect
 a narrow therapeutic index
 numerous dietary and drug interactions
 a variable anticoagulation response
 a requirement for frequent
anticoagulation monitoring
 This prompted the development of novel
oral anticoagulants which directly target
crucial steps in the coagulation cascade,
either Factor Xa or thrombin (Factor IIa).
Dabigatran etexilate, hereafter referred to
as dabigatran, is an oral direct thrombin
inhibitor, and the first of the novel
anticoagulants to gain widespread use in
the U.S. for anticoagulation in the setting of
non-valvular AF.
 There is no currently available reversal
agent for dabigatran, although it is
dialyzable. Because of the predominant
renal elimination, kidney dysfunction can
also predispose to potential bleeding
complications. As the use of dabigatran
began to increase in the community, an
initial surveillance of associated bleeding
episodes in a neuroscience hospital was
characterized.

METHODS

RESULTS (CONTINUED)

 An emergency management team including
the pharmacy, nephrology, hematology
and/or vascular medicine consult services
were notified when patients were admitted to
the hospital for dabigatran - associated
intracranial bleeding.
 These patients had their hospital course
followed for an ongoing quality assessment
of how to best manage these occurrences
and help prevent them in the future.

RESULTS

These data highlight the difficulty with
monitoring effect of anticoagulation with
traditional anticoagulation monitoring
techniques. Although a presumed benefit of
the novel anticoagulants is not needing to be
monitored, there are instances where effect
may need to be quantified. Additionally, the
adverse events noted were in the elderly and
those with compromised renal function.
aPTT values for 5 patients according to time collection

 5 cases of intracranial bleeding associated
with dabigatran occurred from 12/20114/12. All patients were on anticoagulation
for AF, the most commonly prescribed dose
of dabigatran was 150 mg BID.
Case 1: 79 year old male with PMH of paroxysmal AF, HTN,
CAD, coronary bypass, bioprosthetic aortic valve replacement
and COPD presented to an outside hospital (OSH) with acute
onset of right sided weakness and facial droop. Outpatient
dabigatran dose had been 75 mg po BID. A CT scan of the
head showed a left basal ganglia intraparenchymal
hemorrhage (3 x 2.1cm) with mild edema and no midline shift.
The patient was transferred to our institution and a repeat CT
scan of the head showed an irregular left lentiform nucleus
hemorrhage of 3.7 x 2.5 cm with surrounding edema.
Admission laboratory values revealed an aPTT of 54 seconds
(reference range: 20-38 s), PT 17.5 s (reference range: 11.214.8 s) and an INR of 1.48. Hemodialysis (HD) was initiated for
4 hrs (Day 1). Following HD, the aPTT declined to 41 s with a
repeat assay showing 55 s six hrs later. A second HD session
for 3.5 hrs was initiated on Day 2 for worsening mental status
in the setting of an elevated aPTT. After the second dialysis
session the aPTT decreased to 40 s. In an attempt to
normalize the aPTT, the pt also received rFVIIa (NovosevenR)
1560 mcg IV x 1 on Day 2. Repeat CT head showed no interval
change in the hemorrhage and combined MRI/MRA was
negative for aneurysm. The aPTT values remained elevated for
37 hours.
Case 2: 84 year old woman with a history of AF, HTN,
hypothyroidism, depression, and cutaneous vasculitis
presented to an OSH with right sided weakness, facial droop;
outpatient dabigatran dose had been 150 mg po BID. Head CT:
1.7 x 2.4 cm hyperdensity in left thalamus. On admission,
aPTT was 60 s, PT was 18.1 s and INR was 1.54. aPTT was
elevated for 37 hours. No dialysis was initiated.
Case 3: 80 year old woman with a PMH of HTN, AF, and CAD
presented following a fall at home to an outside emergency
department. On arrival a CT scan of the head showed a
subarachnoid hemorrhage (SAH). Dabigatran dose had been
150 mg po BID. On transfer to our facility, a repeat CT scan of
the head showed interval development of a large SAH within
the suprasellar cistern, right perimesencepahlic cistern, and
the left prepontine cistern. On admission, aPTT was 60 s, PT
was 16.8 s, and INR = 1.4. She had 3 sessions of hemodialysis
during days 1 and 2 of hospitalization. Received 4 units FFP
and 10 units platelets. Repeat imaging showed no interval
change in the hemorrhage. The aPTT value after 2 sessions of
HD was 36 s; aPTT remained elevated for 28 hours.

DISCUSSION

We assert the necessity of needing an
anticoagulation stewardship program that
prepares institutions for the introduction of
novel anticoagulants. Essential elements for
this type of program include:
•
•
•

Days in ICU

Education of appropriate dosing and indications.
Plan for management of adverse events including
mobilization of dialysis team with involvement of
nephrology and vascular/hematology specialists.
Continuous monitoring for adverse events to target
areas of prevention.

, Total Length of Stay (Days)

CONCLUSIONS

Case 4: 83 year old man with PMH of AF, cardiomyopathy,
(ejection fraction 15%), AICD with pacemaker, COPD and
severe aortic stenosis ,with a valve area of 0.8 cm2 was
admitted with a subdural hemorrhage and cardiogenic
shock. He developed progressive multi-organ failure. On
admission, aPTT 32 s, PT 15.9 s, and INR 1.3. The patient
expired during the hospitalization. Dabigatran dose was
unknown. No dialysis was initiated.
Case 5: 90 old female with a history of HTN, CAD, AF, and
both a hip and knee replacement was found on the floor
after a fall and was transferred from an OSH. Initial
laboratory evaluation demonstrated a PT of 22.3 sec,
corresponding INR of 2.1, and an aPTT of 65.2 s. CT scan
of the head demonstrated a left temporo-pariatal acute
subdural hemorrhage (SDH) measuring 7 mm, a SAH in
the sylvian fissure and supracellar cistern, as well as trace
intraventricular hemorrhage. On transfer, repeat imaging
again demonstrated multicompartmental hemorrhage,
with evolution. Initial aPTT value was 39 s, PT was 21.8 s,
with INR of 1.97. Following a session of high flux
hemodialysis for 4 hours the aPTT was 41 s. The patient
dislodged her own hemodialysis catheter , however,
remained clinically stable with no interval changes on the
repeat imaging. Accordingly, no further intervention was
required. The aPTT values remained elevated for 27
hours.

• Appropriate patient selection is required
to prevent dabigatran associated AE
• Advanced age and kidney dysfunction
are high risk groups for AE.
• aPTT values may remain prolonged for
extended periods.
• Hospitals need a defined management
plan for AE and major bleeding
associated with novel anticoagulants
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